Tag: obesity

INSANE: “Fat Queer” Communist Activist Declares GLP-1 Weight-Loss Drugs “Fascistic” — Claims Society Is “Genociding Fat People”

The radical left has apparently discovered its latest form of “fascism”: Americans using medication to lose weight and improve their health.

During the four-day Socialism 2026 conference in Chicago, self-described Black, fat, queer anarcho-communist activist Da’Shaun L. Harrison launched a bizarre attack on popular GLP-1 medications such as Ozempic, claiming the drugs represent a new phase of so-called “body fascism” while delivering the remarks in a face mask.

Harrison made the remarks during a September 5 panel titled “Health Fascism, Body Politics, and the Anti-State State.”

Harrison: “The political deployment of GLP-1s is fascistic, not because individuals take them, but because the conditions under which they become necessary are shaped by a world fixated on genociding fat people.

A shot that helps diabetics, heart patients, and obese Americans lose dangerous weight is, in this worldview, a tool of genocide.

Harrison did not stop there. The author of Belly of the Beast: The Politics of Anti-Fatness as Anti-Blackness, a self-described Afropessimist, anarcho-communist, and trans theorist who uses they/them pronouns, tied the entire obesity debate to race, slavery, and “colonial surveillance.”

“This is a structural critique that asks what happens when the conditions produced by capitalism, by public health, by the state apparatus, and by anti-black desire align around a single bodily ideal that leaves little to no room for divergence and punishes any body that does.”

And then the academic name-drop:

“But to understand why the deployment of GLP-1s is fascistic requires turning to Frantz Fanon’s account of black flesh under colonial surveillance.”

BMI charts. Diet culture. Doctors telling patients they are overweight. All of it, according to Harrison, is “body fascism” built on the policing of “Black fat flesh.”

Keep reading

Pharmacists sound alarm over popular drugs used for weight loss: Users ‘look like chemo patients’

Drugs prescribed for diabetes and chronic obesity such as Ozempic are increasingly sought after for quick, cosmetic weight loss, a life choice pharmacists warn can lead to serious health risks. 

“We have seen thin people try to come in and get it,” Dr. Carrie Leske, a licensed pharmacist in Minnesota, recently told Just the News. “As pharmacists we are supposed to use our judgment and, if need be, call the physician and try to understand what’s going on, because it’s supposed to only be used for obese people.”

Such prescription medications, known under such popular brand names as Ozempic and Wegovy, are a class of drugs known as Glucagon-like peptide-1 receptor agonists (or GLP-1s) that mimic a natural hormone to lower blood sugar and reduce appetite. Two types of GLP-1s – semaglutide and tirzepatide – are found in such medications. 

However, they were not created for weight loss in people already at healthy weights. So taking it off-label brings such serious medical risks as severe dehydration, muscle loss and pancreatitis.

“Some of the people using [these] just look so unhealthy,” Leske, also told Just the News. “They look like chemo patients to me.”

Dr. Nairi Kasparian, a clinical pharmacist in Omaha, told Just the News that while GLP-1s can be “very effective,” they are designed for continual, indefinite use as long-term weight management – not necessarily as a temporary weight loss pill.

“They are FDA-approved as chronic weight-management treatments, meaning the goal is generally to continue them as long as they are providing benefit and are tolerated,” she said. 

“The biggest issue is when people stop taking the drug,” said Kasparian, while also pointing out “current obesity-treatment guidance notes that stopping semaglutide or tirzepatide abruptly can result in regaining roughly half to two-thirds of the weight lost within a year” – particularly if the individual has not maintained a strict diet.

Nevertheless, the efficacy of the medications in curbing appetite and delivering speedy results has gained the attention of otherwise healthy individuals seeking short-term, cosmetic weight loss.

Keep reading

Scientists Warn of Vision and Nerve Side Effects from GLP-1 Drugs

Vision problems often develop quietly, with no pain or early warning, yet once eyesight is damaged it’s rarely restored. That’s why any new evidence linking popular medications to sudden changes in eye health deserves your attention. GLP-1 receptor agonists, marketed under names like Ozempic and Wegovy, are being taken by millions of people worldwide, not only for Type 2 diabetes but also as quick solutions for weight loss.

These drugs have been hailed as breakthroughs, but their effects on human health, including the eyes, tell a more complicated story. Emerging research suggests that their influence on vision could trigger unexpected harm.

For those already managing diabetes or for individuals considering these drugs solely for weight management, the stakes may be high because eye-related changes can be lasting. Understanding how they affect the delicate tissues of your eyes is central to protecting your long-term health. That is why new studies examining their role in vision changes are so important, offering insight into the risks tied to their use.

Keep reading

RFK Jr. Announces Obesity Rates in America Are Down for the First Time in Half a Century

Health and Human Services Secretary Robert F. Kennedy Jr. announced Tuesday that the obesity rate in the United States dropped last year for the first time in half a century.

Speaking at an event hosted by America First Policy Institute in Charlotte, Michigan, Kennedy said, “Since President [Donald] Trump came into office, obesity rates in this country have dropped by 2.5 percent. That’s the first drop in 50 years. And that drop alone will have significant impacts on health care costs in this country, because obesity drives about 80 percent of chronic disease.”

Health care costs account for approximately 35 percent of federal expenditures, according to the most recent data from the Treasury Department.

In fiscal year 2024, the federal government spent $1.9 trillion on health care programs, making it the largest category of federal spending.

“Thirty-five percent of American adults are obese,” RFK Jr. said. “When my uncle [John F. Kennedy] was president [in the early 1960s], 3 percent of children were obese. Now, it’s 20 percent.”

Keep reading

‘You’ve Got to be Freaking Kidding Me’: U.S. Military Spends Over $700 Million for Ozempic and Other GLP-1 Weight Loss Meds

Military personnel criticize the hundreds of millions spent on weight loss medications as a misguided approach to addressing the obesity crisis in the U.S. Armed Forces.

A report from the American Security Project in 2025 revealed that approximately 68 percent—two out of three—of the military’s Reserve and National Guard forces are classified as overweight.

Subsequent to this report, Secretary of War Pete Hegseth expressed his concern on X, stating, “Completely unacceptable. This is what happens when standards are IGNORED – and this is what we are changing. REAL fitness & weight standards are here. We will be FIT, not FAT.”

Was the solution found in raising the bar for “REAL fitness & weight standards?” Perhaps they were. However, some startling revelations concerning weight loss have emerged, with RealClearInvestigations dubbing this disclosure the “Waste of the Day.”

Since 2021, the military has allocated nearly $726 million for Ozempic and other GLP-1 weight loss medications, with $274.6 million spent in fiscal year 2025, as revealed by spending records acquired by Open the Books.

This expenditure encompasses 102,597 individual purchases, all made through the Defense Logistics Agency for “troop support.” The majority of the funds were directed to the wholesale pharmaceutical company Cencora. Over a dozen varieties of GLP-1 medications were acquired, including Wegovy, Mounjaro, and Trulicity.

Many individuals—and taxpayers alike—who have served in the military are infuriated.

Lt. Ted Macie, a retired Navy Medical Service Corps officer, was appalled. He informed The Gateway Pundit that data obtained from the Defense Medical Epidemiology Database (DMED) indicate that obesity rates have surged in the military over the last decade.

From 2016 to 2019, an average of 13,863 cases of overweight and obesity were documented across all branches of service. This average rose to 21,969 between 2020 and 2023. Remarkably, there was a 190 percent increase during this period, with cases soaring from 12,249 to 35,531.

Keep reading

FDA Grants Speedy Approval to Eli Lilly’s Weight-Loss Pill for Obesity

Federal regulators on Wednesday approved Eli Lilly’s new weight-loss pill, a second daily oral medication to treat obesity and other weight-related conditions.

The Food and Drug Administration granted expedited approval to orforglipron, a GLP-1 drug that works like widely used injectable medications to mimic a natural hormone that controls appetite and feelings of fullness.

The drug, which will be branded as Foundayo, is expected to begin shipping Monday. The company said people with insurance may be able to get the drug starting at $25 per month with a Lilly discount card. Prices for people paying cash will range between $149 per month to $349 per month, depending on the dose.

The new pill joins drugmaker Novo Nordisk’s oral Wegovy pill, which has spurred more than 600,000 prescriptions in the United States since it was approved in December.

The FDA authorized Eli Lilly’s drug as part of a new program aimed at cutting drug approval times. The agency said it reviewed the company’s application in 50 days.

In a clinical trial of more than 3,000 adults with obesity, participants who received the highest dose of orforglipron, 36 milligrams, lost 11.2% of their body weight — about 25 pounds on average — over more than 16 months. That compared with a 2.1% weight loss, or less than 5 pounds, in patients who received a placebo, or dummy pill, according to the New England Journal of Medicine.

Keep reading

Hims and Hers Stops Offering Semaglutide Drugs Following FDA Scrutiny

Telehealth business Hims and Hers will stop offering customers pills made of compounded semaglutide, which is used for weight loss and diabetes control, the company said in a Feb. 7 post on X.

Compounded drugs are medications created by licensed pharmacists or physicians by mixing and combining the various ingredients of a drug. These are not approved by the Food and Drug Administration, as a result of which their safety, quality, and effectiveness remain suspect. Semaglutide is the active ingredient of medications such as Ozempic and Wegovy, which are GLP-1 drugs used to treat diabetes and weight loss.

On Feb. 5, Hims and Hers announced it was offering compounded semaglutide to customers.

“This new option features a specialized formulation that is engineered to protect the active ingredient through digestion and support absorption,” it said.

The company offered introductory plans beginning at $49 from the first month, with a 5-month plan. Hims and Hers claimed it adhered to “all federal and state standards for compounding.” Moreover, all active pharmaceutical ingredients used in the compounded drugs are exclusively sourced from facilities registered with the FDA, according to the company.

In a Feb. 5 post on X, FDA Commissioner Dr. Marty Makary said the agency would take “swift action” against companies that mass-market copycat drugs with a claim that they are similar to FDA-approved products.

Keep reading

Ozempic’s HIDDEN DANGERS: Weight Loss Jabs Linked To HIGHER Risks of Cancer, Heart Issues, And Chronic Disease

Big Pharma’s miracle injections are under fire again as new research uncovers how Ozempic and similar GLP-1 drugs could be setting users up for severe long-term health traps. 

A new study suggests that slamming the brakes on appetite, these medications risk starving the body of essential nutrients, paving the way for elevated dangers of heart problems, chronic illnesses, and even certain cancers. 

It’s another stark reminder of how the medical-industrial complex prioritizes profits over genuine wellness, leaving Americans to pay the price.

In a landscape where synthetic fixes are pushed over real food and lifestyle reforms, this revelation is stark. With millions hooked on these jabs, the findings demand scrutiny—especially as the media downplays the risks while pushing the hype.

A recent review by Australia’s Hunter Medical Research Institute and the University of Newcastle analyzed 41 randomized controlled trials on popular GLP-1/GIP medications spanning the last 17 years. 

Shockingly, only two studies tracked dietary intake among adults, and one remains unpublished. This glaring “blind spot” highlights how little we know about the nutritional impacts of these drugs, despite their skyrocketing use.

The core issue is appetite suppression. While users shed weight, they often consume far fewer calories and nutrients, leading to deficiencies that can trigger inflammation, metabolic chaos, and heightened vulnerability to serious conditions. 

As the researchers warn, inadequate nutrition “can increase the risk of cardiovascular disease, metabolic complications, inflammation and long-term chronic conditions, including some cancers.”

At least half a million Australians are jabbing these drugs monthly, amid ongoing shortages. In the U.S., the numbers are even higher, with Ozempic and its cousins like Mounjaro becoming go-to prescriptions for obesity and diabetes.

Separate studies have already flagged mixed signals on direct cancer links. A 2025 JAMA Oncology paper found GLP-1 drugs associated with an overall 17% lower cancer risk, but with a potential uptick in kidney cancer. 

Keep reading

Weight-loss jab users are being left with debilitating new side-effect, one of the UK’s leading orthopaedic surgeons warns

Weight-loss jab users are being left with a devastating new side-effect, a top surgeon has warned.

The alarming trend spotted amongst GLP-1 users means some patients cannot lift their limbs due to nerve dysfunction.

One of the UK’s leading orthopaedic surgeons, Tim Sinnett, has said he ‘expects to see more patients presenting these symptoms over time’.

The Foot and Ankle Surgeon, who is part of the prestigious Grosvenor Orthopaedic Partners group, added: ‘In the past six months, I have seen a handful of patients with foot drop related to weight-loss jabs – a phenomenon which has only presented itself this year.

‘The sudden loss of weight, associated with this medication, is what is causing the problem.

‘All nerves have a natural rim of fat around them. Suddenly losing weight, and the fat surrounding nerves, can cause this nerve dysfunction in the foot and ankle.

‘Patients with foot drop can have difficulty lifting the front part of the foot, causing it to drag on the floor.

‘Although losing weight is generally beneficial for the feet and ankles, in terms of reducing the force on the joints, the speed of the weight loss appears to be causing the nerves to malfunction.

Keep reading

There may not be a safe off-ramp for some taking GLP-1 drugs, study suggests

The popularity of GLP-1 weight-loss medications continues to soar—and their uptake is helping to push down obesity rates on a national scale—but a safe, evidence-based way off the drugs isn’t yet in clear view.

An analysis published this week in JAMA Internal Medicine found that most participants in a clinical trial who were assigned to stop taking tirzepatide (Zepbound from Eli Lilly) not only regained significant amounts of the weight they had lost on the drug, but they also saw their cardiovascular and metabolic improvements slip away. Their blood pressure went back up, as did their cholesterol, hemoglobin A1c (used to assess glucose control levels), and fasting insulin.

In an accompanying editorial, two medical experts at the University of Pittsburgh, Elizabeth Oczypok and Timothy Anderson, suggest that this new class of drugs should be rebranded from “weight loss” drugs to “weight management” drugs, which people may need to take indefinitely.

Some studies have found that about half of people who start taking a GLP-1 drug for weight loss stop taking it within a year—for various reasons—and many people think they can stop taking anti-obesity drugs once they’ve reached a desired weight, Oczypok and Anderson write. But that’s not in line with the data.

“It may be helpful to compare them to other chronic disease medications; patients do not stop their anti-hypertensive medications when their blood pressure is at goal,” they write.

In the trial, researchers—led by Eli Lilly scientists—followed 670 participants with obesity or overweight (but without diabetes) who were treated with tirzepatide for 36 weeks. Then the participants were split into either continuing with the drug for another 52 weeks (88 weeks total) or getting a placebo for that period of time. Both groups were told to continue a reduced-calorie diet and an exercise plan.

In all, 335 participants were randomized to switch to a placebo, and the researchers monitored changes in their weight and cardiovascular health metrics after the switch. Not everyone in the first phase of the trial lost significant amounts of weight on the drug. So, the researchers only closely tracked the 308 of the 335 who lost at least 10 percent of their body weight on the drug.

Of the 308 who benefited from tirzepatide, 254 (82 percent) regained at least 25 percent of the weight they had lost on the drug by week 88. Further, 177 (57 percent) regained at least 50 percent, and 74 (24 percent) regained at least 75 percent. Generally, the more weight people regained, the more their cardiovascular and metabolic health improvements reversed.

Keep reading